SL1009 PDUFA Dec. 30: Ultra-Rare Mitochondrial Disease PDCD

Saol Therapeutics, a privately held company based in Roswell, Georgia, announced that the FDA accepted its NDA resubmission for SL1009 (sodium dichloroacetate, or DCA) for the treatment of pyruvate dehydrogenase complex deficiency (PDCD). The FDA classified the resubmission as Class 2 with Priority Review and set a PDUFA target action date of December 30, 2026. PDCD is a rare, life-threatening mitochondrial disease with no FDA-approved therapies.

This is the second FDA review cycle. Saol submitted the original NDA on November 27, 2024. The FDA issued a Complete Response Letter on August 27, 2025, requesting additional survival analyses. The CRL did not flag safety or manufacturing concerns. Saol held a Type A meeting in December 2025 and a Type C meeting in March 2026, then resubmitted the NDA on June 30, 2026 with the requested data. For context on what a CRL means and how the resubmission cycle works, see our guide to Complete Response Letters.

PDCD is an inherited mitochondrial disorder that prevents cells from converting pyruvate to acetyl-CoA, starving the brain and muscles of energy. The result is chronic lactic acidosis, profound developmental delay, and early childhood death. Estimated incidence is roughly 1 in 50,000 live births, making it one of the rarest mitochondrial diseases. DCA works by inhibiting pyruvate dehydrogenase kinase, keeping the pyruvate dehydrogenase complex active so more pyruvate enters the Krebs cycle instead of accumulating as lactate. The pharmacology has been understood for decades, but no sponsor had pursued FDA approval until Saol.

A notable feature of this filing is the companion diagnostic. SL1009, if approved, will be used with a proprietary dose-determining genetic test that Saol is filing as a 510(k) with Medosome Biotec. The test identifies patients with genetic profiles most likely to respond and determines dosing based on genotype. This is a novel regulatory approach for a small molecule, pairing an NDA with a device submission. The FDA must clear both the drug and the diagnostic for SL1009 to reach patients.

SL1009 carries Orphan Drug, Priority Review, and Rare Pediatric Disease designations. Upon approval, Saol anticipates receiving a Priority Review Voucher under the Rare Pediatric Disease statute. These vouchers have sold for over $100 million in private transactions, according to BioSpace’s analysis of disclosed PRV sales. For a private company with no revenue, the voucher represents a material asset. Saol could sell it to a larger company looking to accelerate review of a high-value drug.

The risk is the CRL history. The FDA already rejected this application once. Second-cycle approval rates after a CRL are meaningfully below 50 percent. The additional survival analyses may or may not satisfy the FDA’s concerns. The agency could request further data, issue a second CRL, or require an advisory committee. The companion diagnostic adds regulatory complexity because the device review and the drug review must converge. If the 510(k) is delayed or rejected, the drug approval could stall even if the clinical data are sufficient.

Investors cannot trade Saol directly because it is private. The story matters for readers tracking the rare disease PDUFA calendar and the broader pattern of ultra-rare pediatric drug approvals. A comparable case is Beren Therapeutics’ adrabetadex NDA for Niemann-Pick Type C, another ultra-rare pediatric disease where the FDA extended the review timeline rather than deciding. Both cases illustrate how the FDA handles single-program filings in diseases with no approved treatments.

What to watch next: whether the FDA schedules an advisory committee meeting before December 30. No AdCom has been announced. If the FDA holds one, the vote signals approval odds before the PDUFA date.

Source: Saol Therapeutics press release on PR Newswire